Bevacizumab: A Review of Its Use in Advanced Cancer, Drugs, vol.32, issue.13, pp.1891-925, 2014. ,
DOI : 10.1007/s40265-014-0302-9
Normalizing tumor vasculature with antiangiogenic therapy: A new paradigm for combination therapy, Nature Medicine, vol.7, issue.9, pp.987-996, 2001. ,
DOI : 10.1038/nm0901-987
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy, Science, vol.307, issue.5706, pp.58-62, 2005. ,
DOI : 10.1126/science.1104819
Bevacizumab-improved distribution of paclitaxelpaclitaxel in ovarian cancer xenografts potentiates antitumor eficacy, Annual meeting AACCR, p.3377 ,
Critical role of bevacizumab scheduling in combination with presurgical chemo-radiotherapy in MRI-deined high-risk locally advanced rectal cancer: results of the branch trial, Oncotarget, vol.6, pp.30394-407, 2015. ,
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme), BMC Cancer, vol.85, issue.5, pp.2016-2026, 2016. ,
DOI : 10.1002/cyto.a.22730
Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model, Targeted Oncology, vol.31, issue.2, pp.189-98, 2015. ,
DOI : 10.1007/s11523-014-0334-9
Computational oncology ??? mathematical modelling of drug regimens for precision medicine, Nature Reviews Clinical Oncology, vol.32, issue.4 ,
DOI : 10.1007/s00280-014-2546-1
Continuous and Discrete Mathematical Models of Tumor-induced Angiogenesis, Bulletin of Mathematical Biology, vol.60, issue.5, pp.857-99, 1998. ,
DOI : 10.1006/bulm.1998.0042
MATHEMATICAL MODELING OF TUMOR-INDUCED ANGIOGENESIS, Annual Review of Biomedical Engineering, vol.8, issue.1, pp.233-57, 2006. ,
DOI : 10.1146/annurev.bioeng.8.061505.095807
A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy, Journal of Theoretical Biology, vol.260, issue.4, pp.545-62, 2009. ,
DOI : 10.1016/j.jtbi.2009.06.026
URL : https://hal.archives-ouvertes.fr/inria-00440447
Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice, Journal of Theoretical Biology, vol.320, pp.86-99, 2013. ,
DOI : 10.1016/j.jtbi.2012.12.013
URL : https://hal.archives-ouvertes.fr/hal-00785876
Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy, Cancer Res, vol.59, pp.4770-4775, 1999. ,
Predictive pharmacokinetic???pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts, Cancer Chemotherapy and Pharmacology, vol.12, issue.4770, pp.1147-57, 2013. ,
DOI : 10.1007/s00280-013-2107-z
Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings, CPT: Pharmacometrics & Systems Pharmacology, vol.47, issue.2, pp.720-727, 2015. ,
DOI : 10.1002/psp4.12045
A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology, Comptes Rendus Mathematique, vol.350, issue.1-2, pp.23-31, 2012. ,
DOI : 10.1016/j.crma.2011.11.019
URL : https://hal.archives-ouvertes.fr/hal-00641476
Fractal Characteristics of Tumor Vascular Architecture During Tumor Growth and Regression, Microcirculation, vol.4, issue.4, pp.395-402, 1994. ,
DOI : 10.3109/10739689709146803
Role of Tumor Vascular Architecture in Nutrient and Drug Delivery: An Invasion Percolation-Based Network Model, Microvascular Research, vol.51, issue.3, pp.327-373, 1996. ,
DOI : 10.1006/mvre.1996.0031
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases, Nature Reviews Drug Discovery, vol.7, issue.6, pp.417-444, 2011. ,
DOI : 10.1038/nrd3455
Biomarkers and Response to Bevacizumab--Letter, Clinical Cancer Research, vol.20, issue.4, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-2763
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer, Proceedings of the National Academy of Sciences, vol.112, issue.5, pp.1547-52, 2015. ,
DOI : 10.1073/pnas.1424024112
Therapeutic Implications from Sensitivity Analysis of Tumor Angiogenesis Models, PLOS ONE, vol.41, issue.3, p.2015, 2017. ,
DOI : 10.1371/journal.pone.0120007.t002
Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data, Biology Direct, vol.70, issue.4 Suppl, pp.12-22, 2016. ,
DOI : 10.1186/s13062-016-0114-9
Determinants of Paclitaxel Penetration and Accumulation in Human Solid Tumor, J Pharmacol Exp Ther, vol.290, pp.871-80, 1999. ,